Sphera Funds Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Sphera Funds Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-92,200	Closed	-$2.13M	–	104
2023 Q1	$2.13M	Sell	92,200 -35,000	-28%	-$834K	0.36%	62
2022 Q4	$3.33M	Sell	127,200 -407,158	-76%	-$9.02M	0.72%	37
2022 Q3	$10.5M	Sell	534,358 -109,373	-17%	-$2.19M	1.46%	17
2022 Q2	$11.3M	Buy	643,731 +150,054	+30%	+$2.36M	1.2%	17
2022 Q1	$8.08M	Buy	493,677 +382,024	+342%	+$5.19M	1.14%	24
2021 Q4	$1.82M	Buy	+111,653	New	+$1.59M	0.2%	78
2021 Q2	–	Sell	-101,666	Closed	-$1.58M	–	182
2021 Q1	$1.58M	Sell	101,666 -100,000	-50%	-$1.63M	0.12%	122
2020 Q4	$3.2M	Buy	+201,666	New	+$3.04M	0.28%	79
2016 Q4	–	Sell	-28,000	Closed	-$1.74M	–	122
2016 Q3	$1.74M	Sell	28,000 -6,000	-18%	-$424K	0.28%	79
2016 Q2	$1.92M	Hold	34,000	–	–	0.5%	62
2016 Q1	$2.18M	Buy	34,000 +10,000	+42%	+$809K	0.47%	43
2015 Q4	$3.38M	Buy	+24,000	New	+$3.26M	0.49%	47

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sphera Funds Management's KDNY Position: Q2 2023 in Review

Sphera Funds Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 92,200 shares — an estimated $2.13M sold.

Sphera Funds Management first reported a position in KDNY in Q4 2015 and held it in 12 quarters. The position peaked at $11.3M in Q2 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Sphera Funds Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Sphera Funds Management sold 92,200 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.13M.
Sphera Funds Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 12 quarters.
Sphera Funds Management's Chinook Therapeutics, Inc. Common Stock position peaked at $11.3M in Q2 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Sphera Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.